A Phase 2 Multicenter, Randomized, Doubleblind, Placebo-Controlled, Dose Range Finding Study to Evaluate the Efficacy and Safety of Intramuscular Injection of Human Placenta-derived Cells (Pda-002) in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2018
At a glance
- Drugs PDA 002 (Primary)
- Indications Diabetic foot ulcer; Peripheral arterial disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celgene Corporation; Celularity
- 09 May 2017 Planned End Date changed from 30 Jul 2018 to 14 Nov 2018.
- 09 May 2017 Planned primary completion date changed from 30 Jul 2018 to 14 Nov 2018.
- 31 Mar 2017 Status changed from recruiting to active, no longer recruiting.